Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

No immediate coverage for blood-based tests for pre-eclampsia in Norway

01 Oct 2020

The New Method framework was established in Norway in 2013 for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. All innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is presented via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at the national level, followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

Blood-based tests for pre-eclampsia were evaluated within the New Method framework since 2018. The Norwegian Institute of Public Health (NIPH) performed health technology assessment and published the report in June 2020.

On August 31, 2020, Decision Forum issued their decision, providing the following statements:

  • Blood-based tests for pre-eclampsia will not be introduced now
  • NIPH assessment shows a lack of evidence on the usefulness of this type of test. The added value of using these tests in clinical practice is therefore uncertain, and further research is needed
  • The Decision Forum requests a new assessment within one year based on updated knowledge

See more information in Norwegian here

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.